agree with this. Current pricing would operate the company at a...

  1. 774 Posts.
    lightbulb Created with Sketch. 333
    agree with this. Current pricing would operate the company at a breakeven depending on the "bed penetration rate".
    It's quite straightforward maths when you look at the number of beds Painchek need to be breakeven.

    Probably a better metric for "break even" would be cashflow positive as cash determines whether a company raise capital or not..
    That metric depends entirely on the operations spend and capex spend so there would be more variables to consider.

    All in all I hope Painchek eventually get the FDA approval and open a larger market to sell their product.
    That's the critical crux for the investment thesis if they can't acheive the penetration rates in existing markets (AU,UK).
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
4.0¢
Change
-0.005(11.1%)
Mkt cap ! $73.68M
Open High Low Value Volume
4.0¢ 4.0¢ 3.9¢ $4.1K 103.7K

Buyers (Bids)

No. Vol. Price($)
2 96757 4.0¢
 

Sellers (Offers)

Price($) Vol. No.
4.5¢ 126111 3
View Market Depth
Last trade - 15.35pm 01/07/2025 (20 minute delay) ?
PCK (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.